135 results on '"Van Laere, Koen"'
Search Results
2. Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer.
- Author
-
Gebruers, Juanito, Elst, Laura, Baldewijns, Marcella, De Wever, Liesbeth, Van Laere, Koen, Albersen, Maarten, and Goffin, Karolien
- Subjects
SENTINEL lymph node biopsy ,PENILE cancer ,SENTINEL lymph nodes ,LYMPH nodes ,LYMPHANGIOGRAPHY ,COMPUTED tomography ,SINGLE-photon emission computed tomography - Abstract
Background: Penile cancer is characterized by an early lymphatic dissemination. In intermediate and high-risk primary tumors without palpable inguinal lymph nodes, there is a 6–30% risk of micro-metastatic disease. Invasive lymph node staging in these patients is performed using dynamic sentinel lymph node biopsy (DSNB). In this study, the role of DSNB in cN0 penile cancer was studied, evaluating features of sentinel lymph node (SN) visualization and outcome parameters. Patients with penile cancer without inguinal lymph node metastases who were referred for DSNB at our center between January 2015 and May 2021 and had a follow-up period of at least 18 months, were retrospectively included. After injection of 85 ± 20 MBq [
99m Tc]Tc-nanocolloid peritumorally, dynamic, static planar and SPECT/CT imaging was performed. Primary endpoints were sensitivity of the diagnostic procedure, disease-free survival and DSNB-related adverse events. Secondary endpoints were SN detection rate, number of SNs and the number of counts of the most active SN. Results: Seventy-seven penile DSNB procedures in 75 patients (67 ± 11 years) were included. The detection rate of DSNB was 91% and 96% per procedure and groin, respectively. Sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) were 79%, 100%, 97% and 100%, respectively. More SNs were seen on SPECT/CT than on static planar imaging (1.33 vs. 1.17, p = 0.001). The mean counts per SN on static planar imaging was lower compared to SPECT/CT (1343 vs. 5008; p < 0.0001). There was a positive correlation between the total counts of the SN on the static planar image and the SPECT/CT (r = 0.79, p < 0.0001). Only one out of seventy-five patients (1%) experienced DSNB-related adverse events. After 18 months, 58 patients remained disease free (77%), 13 developed local recurrence (17%), and 4 developed lymphatic or distant metastases (5%). Conclusion: DNSB is a safe diagnostic procedure with a good detection rate and in particular high negative predictive value. It can therefore prevent overtreatment of patients with negative inguinal groins on clinical examination and DSNB examination. Finally, DSNB enables an early detection of occult metastases which would not be visualized with standardized imaging modalities. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.
- Author
-
Boeckxstaens, Lennert, Pauwels, Elin, Vandecaveye, Vincent, Deckers, Wies, Cleeren, Frederik, Dekervel, Jeroen, Vandamme, Timon, Serdons, Kim, Koole, Michel, Bormans, Guy, Laenen, Annouschka, Clement, Paul M., Geboes, Karen, Van Cutsem, Eric, Nackaerts, Kristiaan, Stroobants, Sigrid, Verslype, Chris, Van Laere, Koen, and Deroose, Christophe M.
- Subjects
NEUROENDOCRINE tumors ,GADOLINIUM ,MAGNETIC resonance imaging ,INTRAVENOUS injections ,PRACTICAL reason ,PETS - Abstract
Background: Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [
18 F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18 F]AlF-OC PET/CT outperforms [68 Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18 F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18 F]AlF-OC ("incremental lesions"). Methods: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68 Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18 F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient. Results: In total, 195 unique lesions were detected: 167 with [68 Ga]Ga-DOTATATE and 193 with [18 F]AlF-OC. The DR for [18 F]AlF-OC was 99.1% versus 91.4% for [68 Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18 F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18 F]AlF-OC, of which 91% were confirmed by MRI and considered true positives. Conclusion: The DR of [18 F]AlF-OC was numerically higher and non-inferior to the DR of [68 Ga]Ga-DOTATATE. [18 F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18 F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta.clinicaltrials.gov/study/NCT04552847 [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients.
- Author
-
Pauwels, Elin, Celen, Sofie, Baete, Kristof, Koole, Michel, Bechter, Oliver, Bex, Marie, Renard, Marleen, Clement, Paul M., Jentjens, Sander, Serdons, Kim, Van Laere, Koen, Bormans, Guy, and Deroose, Christophe M.
- Subjects
PHARMACOKINETICS ,NEURAL crest ,POSITRON emission tomography ,NORADRENALINE ,NEUROBLASTOMA - Abstract
Purpose: Despite its limitations, [
123 I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18 F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18 F]MFBG and perform a head-to-head comparison with [123 I]MIBG in neural crest tumour patients. Methods: Six neural crest tumour patients (4 phaeochromocytoma, 1 paraganglioma, 1 neuroblastoma) with a recent routine clinical [123 I]MIBG scintigraphy (interval: − 37–75 days) were included. Adult patients (n = 5) underwent a 30-min dynamic PET, followed by 3 whole-body PET/CT scans at 60, 120, and 180 min after injection of 4 MBq/kg [18 F]MFBG. One minor participant underwent a single whole-body PET/CT at 60 min after administration of 2 MBq/kg [18 F]MFBG. Normal organ uptake (SUVmean ) and lesion uptake (SUVmax ; tumour-to-background ratio (TBR)) were measured. Regional distribution volumes (VT ) were estimated using a Logan graphical analysis in up to 6 lesions per patient. A lesion-by-lesion analysis was performed to compare detection ratios (DR), i.e. fraction of detected lesions, between [18 F]MFBG and [123 I]MIBG. Results: [18 F]MFBG was safe and well tolerated. Its biodistribution was overall similar to that of [123 I]MIBG, with prominent uptake in the salivary glands, liver, left ventricle wall and adrenals, and mainly urinary excretion. In the phaeochromocytoma subgroup, the median VT was 37.4 mL/cm3 (range: 18.0–144.8) with an excellent correlation between VT and SUVmean at all 3 time points (R2 : 0.92–0.94). Mean lesion SUVmax and TBR at 1 h after injection were 19.3 ± 10.7 and 23.6 ± 8.4, respectively. All lesions detected with [123 I]MIBG were also observed with [18 F]MFBG. The mean DR with [123 I]MIBG was significantly lower than with [18 F]MFBG (61.0% ± 26.7% vs. 99.8% ± 0.5% at 1 h; p = 0.043). Conclusion: [18 F]MFBG is a promising hNET imaging agent with favourable imaging characteristics and improved lesion targeting compared with [123 I]MIBG scintigraphy. Trial registration: Clinicaltrials.gov: NCT04258592 (Registered: 06 February 2020), EudraCT: 2019-003872-37A. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Simultaneous 18F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use.
- Author
-
Van Laere, Koen, Ceccarini, Jenny, Gebruers, Juanito, Goffin, Karolien, and Boon, Elizabet
- Subjects
- *
VOXEL-based morphometry , *LIMBIC system , *NEUROLOGICAL disorders , *OCCIPITAL lobe , *DISCRIMINANT analysis , *VISUAL cortex , *VISUAL fields , *BRUGADA syndrome - Abstract
Purpose: Visual snow syndrome (VSS) is a recently recognized chronic neurologic condition characterized by the constant perceiving of tiny flickering dots throughout the entire visual field. Metabolic overactivity and grey matter volume increase in the lingual gyrus has been reported. We investigated this by 18F-FDG PET/MR in comparison to healthy controls. Aside from voxel-based characterization, the classification accuracy of volume-of-interest (VOI)-based multimodal assessment was evaluated, also in comparison with visual analysis. Methods: Simultaneous 18F-FDG PET and MR imaging was performed in 7 patients with VSS (24.6 ± 5.7 years; 5 M/2F) and 15 age-matched healthy controls (CON) (28.0 ± 5.3 years; 8 M/7F). SPM12 and voxel-based morphometric analysis was performed. A VOI-based discriminant analysis was performed with relative 18F-FDG uptake, MR grey matter (GM) volumes and their combination. A visual analysis was done by two blinded experienced readers. Results: Relative increased hypermetabolism was found in VSS patients in the lingual gyrus and cuneus (pFWE < 0.05, peak change + 24%), and hypometabolism in the mesiotemporal cortex (pheight,uncorr < 0.001, peak change − 14%). VSS patients also had increased GM volume in the limbic system and frontotemporal cortex bilaterally (pFWE < 0.05), and in the left secondary and associative visual cortex and in the left lingual gyrus (pheight,uncorr < 0.001). Discriminant analysis resulted in 100% correct classification accuracy for 18F-FDG with lingual gyrus, cuneus and lateral occipital lobe (BA 17 and BA 18) as main discriminators. Unimodal MR- and combined 18F-FDG + MR classification resulted in an accuracy of 91% and 95%, respectively. Visual analysis of 18F-FDG was highly observer dependent. Conclusion: Patients with VSS have highly significant structural and metabolic abnormalities in the visual and limbic system. VOI-based discriminant analysis of 18F-FDG PET allows reliable individual classification versus controls, whereas visual analysis of experienced observers was highly variable. Further investigation in larger series, also in comparison to VSS mimicking disorders such as migraine, is warranted. Trail registration: Retrospectively registered at clinicaltrials.gov under NCT05569733 on Oct 5, 2022. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin.
- Author
-
Delva, Aline, Koole, Michel, Serdons, Kim, Bormans, Guy, Liu, Longbin, Bard, Jonathan, Khetarpal, Vinod, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Wood, Andrew, Skinbjerg, Mette, Wang, Yuchuan, Vandenberghe, Wim, and Van Laere, Koen
- Subjects
POSITRON emission tomography ,RADIATION dosimetry ,HUNTINGTIN protein ,NEUROTOXICOLOGY ,ADVERSE health care events - Abstract
Purpose: Huntington's disease is caused by a trinucleotide expansion in the HTT gene, which leads to aggregation of mutant huntingtin (mHTT) protein in the brain and neurotoxicity. Direct in vivo measurement of mHTT aggregates in human brain parenchyma is not yet possible. In this first-in-human study, we investigated biodistribution and dosimetry in healthy volunteers of [
11 C]CHDI-00485180-R ([11 C]CHDI-180R) and [11 C]CHDI-00485626 ([11 C]CHDI-626), two tracers designed for PET imaging of aggregated mHTT in the brain that have been validated in preclinical models. Methods: Biodistribution and radiation dosimetry studies were performed in 3 healthy volunteers (age 25.7 ± 0.5 years; 2 F) for [11 C]CHDI-180R and in 3 healthy volunteers (age 35.3 ± 6.8 years; 2 F) for [11 C]CHDI-626 using sequential whole-body PET-CT. Source organs were delineated in 3D using combined PET and CT data. Individual organ doses and effective doses were determined using OLINDA 2.1. Results: There were no clinically relevant adverse events. The mean effective dose (ED) for [11 C]CHDI-180R was 4.58 ± 0.65 μSv/MBq, with highest absorbed doses for liver (16.9 μGy/MBq), heart wall (15.9 μGy/MBq) and small intestine (15.8 μGy/MBq). Mean ED for [11 C]CHDI-626 was 5.09 ± 0.06 μSv/MBq with the highest absorbed doses for the gallbladder (26.5 μGy/MBq), small intestine (20.4 μGy/MBq) and liver (19.6 μGy/MBq). Decay-corrected brain uptake curves showed promising kinetics for [11 C]CHDI-180R, but for [11 C]CHDI-626 an increasing signal over time was found, probably due to accumulation of a brain-penetrant metabolite. Conclusion: [11 C]CHDI-180R and [11 C]CHDI-626 are safe for in vivo PET imaging in humans. The estimated radiation burden is in line with most11 C-ligands. While [11 C]CHDI-180R has promising kinetic properties in the brain, [11 C]CHDI-626 is not suitable for human in vivo mHTT PET due to the possibility of a radiometabolite accumulating in brain parenchyma. Trial registration : EudraCT number 2020-002129-27. Clinicaltrials.gov NCT05224115 (retrospectively registered). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients.
- Author
-
Vanderlinden, Greet, Mertens, Nathalie, Michiels, Laura, Lemmens, Robin, Koole, Michel, Vandenbulcke, Mathieu, and Van Laere, Koen
- Subjects
AMNESTIC mild cognitive impairment ,POSITRON emission tomography ,CEREBELLAR cortex ,BRAIN imaging ,MELANOCYTES ,MULTIVARIATE analysis - Abstract
Purpose: Neurofibrillary tangles (NFTs) in Alzheimer's disease can be accurately quantified in vivo using [
18 F]MK-6240 PET. Short-term [18 F]MK-6240 test-retest (TRT) is about 6%, but also long-term stability of cerebral uptake is of importance for longitudinal studies. Furthermore, although there is very little cerebral off-target binding, [18 F]MK-6240 shows variable extracerebral uptake (ECU) assumed to represent off-target binding to leptomeningeal melanocytes. Here, we examined 6-month TRT of [18 F]MK-6240 in healthy controls (HC) and investigated ECU in HC and patients with amnestic mild cognitive impairment (aMCI) with up to 2 years of follow-up. We also explored demographic factors that may be associated to ECU, including age, sex, education, smoking, and disease status. Methods: A total cohort of 40 HC (57 ± 19 years, 21F/19 M) and 24 aMCI (72 ± 8 years, 14F/10 M) underwent baseline [18 F]MK-6240 PET-MR (GE Signa), 90–120 min post injection. [18 F]MK-6240 was quantified by standardized uptake value ratios (SUVR) in predefined volumes-of-interest relative to the cerebellar cortex. Ten HC (56 ± 12 years, 8F/2 M) underwent a 6-month follow-up [18 F]MK-6240 to assess TRT. Also, 10 aMCI (72 ± 6 years, 5F/5 M) underwent a 2-year follow-up [18 F]MK-6240 PET-MR. Longitudinal changes in ECU were assessed in both cohorts. ECU was quantified as the mean SUVR of the skull parcel (FreeSurfer 6.0) that includes the meninges. Results: The mean gray matter [18 F]MK-6240 SUVR TRT and absolute TRT in HC were 1.6 ± 3.4% and 2.4 ± 2.8%, respectively. We found no significant 6-month or 2-year differences in ECU in HC (4.4 ± 20%) and aMCI (7.9 ± 19%), respectively. In the total cohort, ECU was significantly correlated to age (rs = − 0.48; p < 0.0001), and a multivariate analysis also showed sex differences (higher ECU in women). Conclusion: [18 F]MK-6240 shows excellent 6-month TRT, which confirms its suitability for quantification of longitudinal NFT changes. The ECU of [18 F]MK-6240 is variable between subjects, influenced by age and sex, but remains stable within subjects over a 2-year time period. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.
- Author
-
Reinartz, Mariska, Luckett, Emma Susanne, Schaeverbeke, Jolien, De Meyer, Steffi, Adamczuk, Katarzyna, Thal, Dietmar Rudolf, Van Laere, Koen, Dupont, Patrick, and Vandenberghe, Rik
- Subjects
OLDER people ,AMYLOID plaque ,ALZHEIMER'S disease ,RECEIVER operating characteristic curves ,SUPPORT vector machines ,GRAIN yields - Abstract
Purpose: End-of-life studies have validated the binary visual reads of
18 F-labeled amyloid PET tracers as an accurate tool for the presence or absence of increased neuritic amyloid plaque density. In this study, the performance of a support vector machine (SVM)-based classifier will be tested against pathological ground truths and its performance determined in cognitively healthy older adults. Methods: We applied SVM with a linear kernel to an18 F-Flutemetamol end-of-life dataset to determine the regions with the highest feature weights in a data-driven manner and to compare between two different pathological ground truths: based on neuritic amyloid plaque density or on amyloid phases, respectively. We also trained and tested classifiers based on the 10% voxels with the highest amplitudes of feature weights for each of the two neuropathological ground truths. Next, we tested the classifiers' diagnostic performance in the asymptomatic Alzheimer's disease (AD) phase, a phase of interest for future drug development, in an independent dataset of cognitively intact older adults, the Flemish Prevent AD Cohort-KU Leuven (F-PACK). A regression analysis was conducted between the Centiloid (CL) value in a composite volume of interest (VOI), as index for amyloid load, and the distance to the hyperplane for each of the two classifiers, based on the two pathological ground truths. A receiver operating characteristic analysis was also performed to determine the CL threshold that optimally discriminates between neuritic amyloid plaque positivity versus negativity, or amyloid phase positivity versus negativity, within F-PACK. Results: The classifiers yielded adequate specificity and sensitivity within the end-of-life dataset (neuritic amyloid plaque density classifier: specificity of 90.2% and sensitivity of 83.7%; amyloid phase classifier: specificity of 98.4% and sensitivity of 84.0%). The regions with the highest feature weights corresponded to precuneus, caudate, anteromedial prefrontal, and also posterior inferior temporal and inferior parietal cortex. In the cognitively normal cohort, the correlation coefficient between CL and distance to the hyperplane was −0.66 for the classifier trained with neuritic amyloid plaque density, and −0.88 for the classifier trained with amyloid phases. This difference was significant. The optimal CL cut-off for discriminating positive versus negative scans was CL = 48–51 for the different classifiers (area under the curve (AUC) = 99.9%), except for the classifier trained with amyloid phases and based on the 10% voxels with highest feature weights. There the cut-off was CL = 26 (AUC = 99.5%), which closely matched the CL threshold for discriminating phases 0–2 from 3–5 based on the end-of-life dataset and the neuropathological ground truth. Discussion: Among a set of neuropathologically validated classifiers trained with end-of-life cases, transfer to a cognitively normal population works best for a classifier trained with amyloid phases and using only voxels with the highest amplitudes of feature weights. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.
- Author
-
Deleu, Anne-Leen, Laenen, Annouschka, Decaluwé, Herbert, Weynand, Birgit, Dooms, Christophe, De Wever, Walter, Jentjens, Sander, Goffin, Karolien, Vansteenkiste, Johan, Van Laere, Koen, De Leyn, Paul, Nackaerts, Kristiaan, and Deroose, Christophe M.
- Subjects
NEUROENDOCRINE cells ,CARCINOID ,POSITRON emission tomography ,SOMATOSTATIN receptors ,RECEIVER operating characteristic curves ,LITERATURE reviews - Abstract
Background: Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited number of studies have evaluated the role of this imaging tool in this specific patient population. The preoperative differentiation between typical carcinoid (TC) and atypical carcinoid (AC) and the extent of dissemination (N/M status) are crucial factors for treatment allocation and prognosis of these patients. Therefore, we performed a pathology-based retrospective analysis of the value of SSTR PET/CT in tumour grading and detection of nodal and metastatic involvement of PC and compared this with the previous literature and with [
18 F]FDG PET/CT in a subgroup of patients. Methods: SSTR PET/CT scans performed between January 2007 and May 2020 in the context of PC were included. If available, [18 F]FDG PET/CT images were also evaluated. The maximum standardized uptake (SUVmax ) values of the primary tumour, of the pathologically examined hilar and mediastinal lymph node stations, as well as of the distant metastases, were recorded. Tumoural SUVmax values were related to the tumour type (TC versus AC) for both SSTR and [18 F]FDG PET/CT in diagnosing and differentiating both tumour types. Nodal SUVmax values were compared to the pathological status (N+ versus N− ) to evaluate the diagnostic accuracy of SSTR PET/CT in detecting lymph node involvement. Finally, a mixed model analysis of all pathologically proven distant metastatic lesions was performed. Results: A total of 86 SSTR PET/CT scans performed in 86 patients with PC were retrospectively analysed. [18 F]FDG PET/CT was available in 46 patients. Analysis of the SUVmax values in the primary tumour showed significantly higher SSTR uptake in TC compared with AC (median SUVmax 18.4 vs 3.8; p = 0.003) and significantly higher [18 F]FDG uptake in AC compared to TC (median SUVmax 5.4 vs 3.5; p = 0.038). Receiver operating characteristic (ROC) curve analysis resulted in an area under the curve (AUC) of 0.78 for the detection of TC on SSTR PET/CT and of 0.73 for the detection of AC on [18 F]FDG PET/CT. A total of 267 pathologically evaluated hilar and mediastinal lymph node stations were analysed. ROC analysis of paired SSTR/[18 F]FDG SUVmax values for the detection of metastasis of TC in 83 lymph node stations revealed an AUC of 0.91 for SSTR PET/CT and of 0.74 for [18 F]FDG PET/CT (difference 0.17; 95% confidence interval − 0.03 to 0.38; p = 0.10). In a sub-cohort of 10 patients with 12 distant lesions that were pathologically examined due to a suspicious aspect on SSTR PET/CT, a positive predictive value (PPV) of 100% was observed. Conclusion: Our findings confirm the higher SSTR ligand uptake in TC compared to AC and vice versa for [18 F]FDG uptake. More importantly, we found a good diagnostic performance of SSTR PET/CT for the detection of hilar and mediastinal lymph node metastases of TC. Finally, a PPV of 100% for SSTR PET/CT was found in a small sub-cohort of patients with pathologically investigated distant metastatic lesions. Taken together, SSTR PET/CT has a very high diagnostic value in the TNM assessment of pulmonary carcinoids, particularly in TC, which underscores its position in European guidelines. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Predictive value of metabolic and perfusion changes outside the seizure onset zone for postoperative outcome in patients with refractory focal epilepsy.
- Author
-
Haemels, Maarten, Van Weehaeghe, Donatienne, Cleeren, Evy, Dupont, Patrick, van Loon, Johan, Theys, Tom, Van Laere, Koen, Van Paesschen, Wim, and Goffin, Karolien
- Published
- 2022
- Full Text
- View/download PDF
11. Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
- Author
-
Jentjens, Sander, Mai, Cindy, Ahmadi Bidakhvidi, Niloefar, De Coster, Liesbeth, Mertens, Nathalie, Koole, Michel, Everaerts, Wouter, Joniau, Steven, Oyen, Raymond, Van Laere, Koen, and Goffin, Karolien
- Subjects
PROSTATE cancer ,LYMPHATIC metastasis ,PETS ,MAGNETIC resonance imaging - Abstract
Objectives: PSMA-PET has become the PET technique of choice to localise the site of biochemically recurrent prostate cancer (PCa). With hybrid PET/MRI, the advantages of MRI are added to molecular characteristic of PET. The aim of this study was to investigate the incremental value of PET/MR versus PET/CT in patients with biochemically recurrent PCa by head-to-head comparison. Methods: Thirty-four patients with biochemically recurrent PCa were prospectively included. They underwent [
68 Ga]Ga-PSMA-11 PET/CT, followed by simultaneous PET/MR. All PET (PETCT , PETMR ), CT and MR images were evaluated for number of lesions and location. The number of lesions at specific sites was compared using Wilcoxon-sign-rank test. For PET, the maximum and mean standardised uptake values (SUVs) were calculated for each lesion compared using a two-sided paired t test. Results: PETCT and PETMR scans were positive in 19 and 20 patients, detecting 73 and 79 lesions respectively. All lesions detected on PETCT were also detected on PETMR . CT and MRI only were positive in 14 and 17 patients, detecting 38 and 50 lesions, respectively, which was significantly lower than PETCT and PETMR respectively. Combined interpretation showed more lesions on PET/MR than on PET/CT (88 vs 81). No significant difference in detection of presence of local recurrence nor distant metastases was found. SUVmean and SUVmax values were significantly higher on PETMR than on PETCT in local recurrence and lymph node metastases. Conclusions: [68 Ga]Ga-PSMA-11 PET/MR was able to detect biochemically recurrent PCa at least as accurately as PET/CT for local recurrence, lymph node metastasis and distant metastasis. Key Points: • PSMA PET/MRI detects the location of biochemical recurrence at least as accurately as PET/CT. • Substitution of PET/CT by PET/MRI adds sensitivity in PSMA lesion detection also in the setting of distant recurrence due to both the MR and TOF PET components. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study.
- Author
-
van Aalst, June, Devrome, Martijn, Van Weehaeghe, Donatienne, Rezaei, Ahmadreza, Radwan, Ahmed, Schramm, Georg, Ceccarini, Jenny, Sunaert, Stefan, Koole, Michel, and Van Laere, Koen
- Subjects
WHITE matter (Nerve tissue) ,DIFFUSION tensor imaging ,PERFUSION ,POLYETHYLENE terephthalate ,GLUCOSE metabolism ,PARIETAL lobe ,TEMPORAL lobe ,GRAY matter (Nerve tissue) ,CROSS-sectional method ,AGE distribution ,MAGNETIC resonance imaging ,AGING ,POSITRON emission tomography ,DESCRIPTIVE statistics ,CEREBRAL cortex - Abstract
Purpose: Human ageing is associated with a regional reduction in cerebral neuronal activity as assessed by numerous studies on brain glucose metabolism and perfusion, grey matter (GM) density and white matter (WM) integrity. As glucose metabolism may impact energetics to maintain myelin integrity, but changes in functional connectivity may also alter regional metabolism, we conducted a cross-sectional simultaneous FDG PET/MR study in a large cohort of healthy volunteers with a wide age range, to directly assess the underlying associations between reduced glucose metabolism, GM atrophy and decreased WM integrity in a single ageing cohort. Methods: In 94 healthy subjects between 19.9 and 82.5 years (mean 50.1 ± 17.1; 47 M/47F, MMSE ≥ 28), simultaneous FDG-PET, structural MR and diffusion tensor imaging (DTI) were performed. Voxel-wise associations between age and grey matter (GM) density, RBV partial-volume corrected (PVC) glucose metabolism, white matter (WM) fractional anisotropy (FA) and mean diffusivity (MD), and age were assessed. Clusters representing changes in glucose metabolism correlating significantly with ageing were used as seed regions for tractography. Both linear and quadratic ageing models were investigated. Results: An expected age-related reduction in GM density was observed bilaterally in the frontal, lateral and medial temporal cortex, striatum and cerebellum. After PVC, relative FDG uptake was negatively correlated with age in the inferior and midfrontal, cingulate and parietal cortex and subcortical regions, bilaterally. FA decreased with age throughout the entire brain WM. Four white matter tracts were identified connecting brain regions with declining glucose metabolism with age. Within these, relative FDG uptake in both origin and target clusters correlated positively with FA (0.32 ≤ r ≤ 0.71) and negatively with MD (− 0.75 ≤ r ≤ − 0.41). Conclusion: After appropriate PVC, we demonstrated that regional cerebral glucose metabolic declines with age and that these changes are related to microstructural changes in the interconnecting WM tracts. The temporal course and potential causality between ageing effects on glucose metabolism and WM integrity should be further investigated in longitudinal cohort PET/MR studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.
- Author
-
de Laat, Bart, Kling, Yvonne E., Schroyen, Gwen, Ooms, Maarten, Hooker, Jacob M., Bormans, Guy, Van Laere, Koen, and Ceccarini, Jenny
- Subjects
ALCOHOL drinking ,ALCOHOLISM ,ALCOHOL ,GLOBUS pallidus ,RATS ,GENE expression ,VOXEL-based morphometry ,BIOLOGICAL models ,IN vivo studies ,ALCOHOL-induced disorders ,ANIMAL experimentation ,RISK assessment ,TEMPERANCE ,DISEASE relapse ,CEREBELLUM ,MEDIUM spiny neurons ,DECISION making ,ESTERASES ,ANXIETY ,LONGITUDINAL method ,DISEASE risk factors - Abstract
Purpose: Phosphodiesterase 10A (PDE10A) is a dual substrate enzyme highly enriched in dopamine-receptive striatal medium spiny neurons, which are involved in psychiatric disorders such as alcohol use disorders (AUD). Although preclinical studies suggest a correlation of PDE10A mRNA expression in neuronal and behavioral responses to alcohol intake, little is known about the effects of alcohol exposure on in vivo PDE10A activity in relation to apparent risk factors for AUD such as decision-making and anxiety. Methods: We performed a longitudinal [
18 F]JNJ42259152 microPET study to evaluate PDE10A changes over a 9-week intermittent access to alcohol model, including 6 weeks of alcohol exposure, 2 weeks of abstinence followed by 1 week relapse. Parametric PDE10A-binding potential (BPND ) images were generated using a Logan reference tissue model with cerebellum as reference region and were analyzed using both a volume-of-interest and voxel-based approach. Moreover, individual decision-making and anxiety levels were assessed with the rat Iowa Gambling Task and open-field test over the IAE model. Results: We observed an increased alcohol preference especially in those animals that exhibited poor initial decision-making. The first 2 weeks of alcohol exposure resulted in an increased striatal PDE10A binding (> 10%). Comparing PDE10A-binding potential after 2 versus 4 weeks of exposure showed a significant decreased PDE10A in the caudate-putamen and nucleus accumbens (pFWE-corrected < 0.05). This striatal PDE10A decrease was related to alcohol consumption and preference. Normalization of striatal PDE10A to initial levels was observed after 1 week of relapse, apart from the globus pallidus. Conclusion: This study shows that chronic voluntary alcohol consumption induces a reversible increased PDE10A enzymatic availability in the striatum, which is related to the amount of alcohol preference. Thus, PDE10A-mediated signaling plays an important role in modulating the reinforcing effects of alcohol, and the data suggest that PDE10A inhibition may have beneficial behavioral effects on alcohol intake. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function.
- Author
-
Mertens, Nathalie, Schmidt, Mark E., Hijzen, Anja, Van Weehaeghe, Donatienne, Ravenstijn, Paulien, Depre, Marleen, de Hoon, Jan, Van Laere, Koen, and Koole, Michel
- Subjects
PURINERGIC receptors ,BLOOD plasma ,POSITRON emission tomography ,ANGIOGRAPHY ,METABOLITES - Abstract
[
18 F]JNJ-64413739 has been evaluated as PET-ligand for in vivo quantification of purinergic receptor subtype 7 receptor (P2X7R) using Logan graphical analysis with a metabolite-corrected arterial plasma input function. In the context of a P2X7R PET dose occupancy study, we evaluated a minimally invasive approach by limiting arterial sampling to baseline conditions. Meanwhile, post dose distribution volumes (VT ) under blocking conditions were estimated by combining baseline blood to plasma ratios and metabolite fractions with an MR angiography driven image derived input function (IDIF). Regional postdose VT,IDIF values were compared with corresponding VT,AIF estimates using a arterial input function (AIF), in terms of absolute values, test–retest reliability and receptor occupancy. Compared to an invasive AIF approach, postdose VT,IDIF values and corresponding receptor occupancies showed only limited bias (Bland–Altman analysis: 0.06 ± 0.27 and 3.1% ± 6.4%) while demonstrating a high correlation (Spearman ρ = 0.78 and ρ = 0.98 respectively). In terms of test–retest reliability, regional intraclass correlation coefficients were 0.98 ± 0.02 for VT,IDIF compared to 0.97 ± 0.01 for VT,AIF. These results confirmed that a postdose IDIF, guided by MR angiography and using baseline blood and metabolite data, can be considered for accurate [18 F]JNJ-64413739 PET quantification in a repeated PET study design, thus avoiding multiple invasive arterial sampling and increasing dosing flexibility. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression.
- Author
-
Takamiya, Akihiro, Vande Casteele, Thomas, Koole, Michel, De Winter, François-Laurent, Bouckaert, Filip, Van den Stock, Jan, Sunaert, Stefan, Dupont, Patrick, Vandenberghe, Rik, Van Laere, Koen, Vandenbulcke, Mathieu, and Emsell, Louise
- Subjects
GRAY matter (Nerve tissue) ,MENTAL depression ,ALZHEIMER'S disease ,PATHOLOGICAL physiology ,BRAIN tomography - Abstract
Late-life depression (LLD) is associated with a risk of developing Alzheimer's disease (AD). However, the role of AD-pathophysiology in LLD, and its association with clinical symptoms and cognitive function are elusive. In this study, one hundred subjects underwent amyloid positron emission tomography (PET) imaging with [
18 F]-flutemetamol and structural MRI: 48 severely depressed elderly subjects (age 74.1 ± 7.5 years, 33 female) and 52 age-/gender-matched healthy controls (72.4 ± 6.4 years, 37 female). The Geriatric Depression Scale (GDS) and Rey Auditory Verbal Learning Test (RAVLT) were used to assess the severity of depressive symptoms and episodic memory function respectively. Amyloid deposition was quantified using the standardized uptake value ratio. Whole-brain voxel-wise comparisons of amyloid deposition and gray matter volume (GMV) between LLD and controls were performed. Multivariate analysis of covariance was conducted to investigate the association of regional differences in amyloid deposition and GMV with clinical factors, including GDS and RAVLT. As a result, there were no significant group differences in amyloid deposition. In contrast, LLD showed significant lower GMV in the left temporal and parietal region. GMV reduction in the left temporal region was associated with episodic memory dysfunction, but not with depression severity. Regional GMV reduction was not associated with amyloid deposition. LLD is associated with lower GMV in regions that overlap with AD-pathophysiology, and which are associated with episodic memory function. The lack of corresponding associations with amyloid suggests that lower GMV driven by non-amyloid pathology may play a central role in the neurobiology of LLD presenting as a psychiatric disorder. Trial registration: European Union Drug Regulating Authorities Clinical Trials identifier: EudraCT 2009-018064-95. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer.
- Author
-
Ahmadi Bidakhvidi, Niloefar, Laenen, Annouschka, Jentjens, Sander, Deroose, Christophe M., Van Laere, Koen, De Wever, Liesbeth, Mai, Cindy, Berghen, Charlien, De Meerleer, Gert, Haustermans, Karin, Joniau, Steven, Everaerts, Wouter, and Goffin, Karolien
- Subjects
HIGH-intensity focused ultrasound ,CANCER relapse ,SOFT tissue tumors ,PROSTATE cancer ,EXTERNAL beam radiotherapy ,RADIOISOTOPE brachytherapy ,DISEASE relapse - Abstract
Background: Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [
18 F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and identify parameters that predict scan positivity as well as the type and number of detected lesions. This monocentric retrospective study included 137 PCa patients with biochemical recurrence who underwent one or more [18 F]PSMA-1007-PET/CT scans between August 2018 and June 2019. PET-positive malignant lesions were classified as local recurrence, lymph node (LN), bone or soft tissue lesions. The association between biochemical/paraclinical parameters, as PSA value, PSA doubling time, PSA velocity, Gleason score (GS) and androgen deprivation therapy (ADT), and scan positivity as well as type and number of detected lesions was evaluated using logistic regression analysis (binary outcomes) and Poisson models (count-type outcomes). Results: We included 175 [18 F]PSMA-1007-PET/CT scans after radical prostatectomy (78%), external beam radiation therapy (8.8%), ADT (7.3%), brachytherapy (5.1%) and high intensity focused ultrasound (0.7%) as primary treatment (median PSA value 1.6 ng/ml). Positivity rate was 80%. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence of bone and soft tissue lesions and number of bone, LN and soft tissue lesions, both in uni- and/or multivariable analysis. Multivariable analysis also showed prior ADT as predictor of bone and soft tissue lesions, GS as predictor of the number of bone lesions and ongoing ADT as predictor of the number of LN lesions. Conclusion: [18 F]PSMA-1007-PET/CT showed a high positivity rate in patients with biochemically recurrent PCa. PSA value and PSA velocity were significant predictors of scan positivity as well as of the presence and number of bone and soft tissue lesions and the number of LN lesions. Our findings can guide clinicians in optimal patient selection for [18 F]PSMA-1007-PET/CT and support further research leading to the development of a prediction nomogram. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density.
- Author
-
Cawthorne, Christopher, Maguire, Paul, Mercier, Joel, Sciberras, David, Serdons, Kim, Bormans, Guy, de Hoon, Jan, Van Laere, Koen, and Koole, Michel
- Subjects
RADIATION dosimetry ,RADIOACTIVE tracers ,POSITRON emission tomography ,SYNAPTIC vesicles ,BLADDER ,ACTIVITY coefficients ,DENSITY - Abstract
Rationale: [
11 C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution and dosimetry estimates derived from sequential whole-body PET using two versions of the OLINDA dosimetry program. Methods: Sequential whole-body PET scans were performed in 3 healthy subjects for 2 h after injection of 254 ± 77 MBq [11 C]-UCB-J. Volumes of interest were drawn over relevant source organs to generate time-activity curves and calculate time-integrated activity coefficients, with effective dose coefficients calculated using OLINDA 2.1 and compared to values derived from OLINDA 1.1 and those recently reported in the literature. Results: [11 C]-UCB-J administration was safe and showed mixed renal and hepatobiliary clearance, with largest organ absorbed dose coefficients for the urinary bladder wall and small intestine (21.7 and 23.5 μGy/MBq, respectively). The average (±SD) effective dose coefficient was 5.4 ± 0.7 and 5.1 ± 0.8 μSv/MBq for OLINDA versions 1.1 and 2.1 respectively. Doses were lower than previously reported in the literature using either software version. Conclusions: A single IV administration of 370 MBq [11 C]-UCB-J corresponds to an effective dose of less than 2.0 mSv, enabling multiple PET examinations to be carried out in the same subject. Trial registration: EudraCT number: 2016-001190-32. Registered 16 March 2016, no URL available for phase 1 trials. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study.
- Author
-
Canosa, Antonio, Calvo, Andrea, Moglia, Cristina, Manera, Umberto, Vasta, Rosario, Di Pede, Francesca, Cabras, Sara, Nardo, Davide, Arena, Vincenzo, Grassano, Maurizio, D'Ovidio, Fabrizio, Van Laere, Koen, Van Damme, Philip, Pagani, Marco, and Chiò, Adriano
- Subjects
POSITRON emission tomography ,AMYOTROPHIC lateral sclerosis ,FACTORIAL experiment designs ,MOTOR cortex ,BRAIN metabolism - Abstract
Purpose: To assess the brain metabolic correlates of the different regional extent of ALS, evaluated with the King's staging system, using brain
18 F-2-fluoro-2-deoxy-d-glucose-PET (18 F-FDG-PET). Methods: Three hundred ninety ALS cases with King's stages 1, 2, and 3 (n = 390), i.e., involvement of 1, 2, and 3 body regions respectively, underwent brain18 F-FDG-PET at diagnosis. King's stage at PET was derived from ALSFRS-R and was regressed out against whole-brain metabolism in the whole sample. The full factorial design confirmed the hypothesis that differences among groups (King's 1, King's 2, King's 3, and 40 healthy controls (HC)) existed overall. Comparisons among stages and between each group and HC were performed. We included age at PET and sex as covariates. Results: Brain metabolism was inversely correlated with stage in medial frontal gyrus bilaterally, and right precentral and postcentral gyri. The full factorial design resulted in a significant main effect of groups. There was no significant difference between stages 1 and 2. Comparing stage 3 to stage 1+2, a significant relative hypometabolism was highlighted in the former in the left precentral and medial frontal gyri, and in the right medial frontal, postcentral, precentral, and middle frontal gyri. The comparisons between each group and HC showed the extension of frontal metabolic changes from stage 1 to stage 3, with the larger metabolic gap between stages 2 and 3. Conclusions: Our findings support the hypothesis that in ALS, the propagation of neurodegeneration follows a corticofugal, regional ordered pattern, extending from the motor cortex to posterior and anterior regions. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
- Author
-
Koole, Michel, Van Weehaeghe, Donatienne, Serdons, Kim, Herbots, Marissa, Cawthorne, Christopher, Celen, Sofie, Schroeder, Frederick A., Hooker, Jacob M., Bormans, Guy, de Hoon, Jan, Kranz, Janice E., Van Laere, Koen, and Gilbert, Tonya M.
- Subjects
RADIOACTIVE tracers ,PROTON magnetic resonance spectroscopy ,POSITRON emission tomography ,AMYOTROPHIC lateral sclerosis ,STATISTICAL reliability ,AKAIKE information criterion ,RADIATION dosimetry ,ENTORHINAL cortex - Abstract
Purpose: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer's disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [
18 F]EKZ-001 ([18 F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. Methods: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (VT ) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. VT differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. Results: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA VT were in agreement with 2TCM VT , however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional VT values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher VT than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. Conclusion: [18 F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Not all black colons on [18F]FDG PET are due to metformin.
- Author
-
Boeckxstaens, Lennert, Vergote, Vibeke, Dierickx, Daan, Tousseyn, Thomas, Bielen, Didier, Van Laere, Koen, Deroose, Christophe M., and Goffin, Karolien
- Subjects
METFORMIN ,INFLAMMATORY bowel diseases ,INFORMED consent (Medical law) ,GASTROINTESTINAL diseases - Abstract
Simultaneously acquired CT images of the [ SP 18 sp F]FDG PET/CT demonstrate wall thickening of the entire colon with mild infiltration of the paracolic fat tissue and some prominent mesenterial lymph nodes. [ SP 18 sp F]FDG PET/CT also demonstrates a liver lesion cranially in the liver and multiple lymph nodes with high [ SP 18 sp F]FDG-uptake. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
21. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients.
- Author
-
Pauwels, Elin, Cleeren, Frederik, Tshibangu, Térence, Koole, Michel, Serdons, Kim, Dekervel, Jeroen, Van Cutsem, Eric, Verslype, Chris, Van Laere, Koen, Bormans, Guy, and Deroose, Christophe M.
- Subjects
SOMATOSTATIN receptors ,RADIATION dosimetry ,BLADDER ,ABSORBED dose ,TUMORS ,POSITRON emission tomography - Abstract
Purpose: The widespread use of gallium-68-labelled somatostatin analogue (SSA) PET, the current standard for somatostatin receptor (SSTR) imaging, is limited by practical and economic challenges that could be overcome by a fluorine-18-labelled alternative, such as the recently introduced [
18 F]AlF-NOTA-octreotide ([18 F]AlF-OC). This prospective trial aimed to evaluate safety, dosimetry, biodistribution, pharmacokinetics and lesion targeting of [18 F]AlF-OC and perform the first comparison with [68 Ga]Ga-DOTATATE in neuroendocrine tumour (NET) patients. Methods: Six healthy volunteers and six NET patients with a previous clinical [68 Ga]Ga-DOTATATE PET were injected with an IV bolus of 4 MBq/kg [18 F]AlF-OC. Healthy volunteers underwent serial whole-body PET scans from time of tracer injection up to 90 min post-injection, with an additional PET/CT at 150 and 300 min post-injection. In patients, a 45-min dynamic PET was acquired and three whole-body PET scans at 60, 90 and 180 min post-injection. Absorbed organ doses and effective doses were calculated using OLINDA/EXM. Normal organ uptake (SUVmean ) and tumour lesion uptake (SUVmax and tumour-to-background ratio (TBR)) were measured. A lesion-by-lesion analysis was performed and the detection ratio (DR), defined as the fraction of detected lesions was determined for each tracer. Results: [18 F]AlF-OC administration was safe and well tolerated. The highest dose was received by the spleen (0.159 ± 0.062 mGy/MBq), followed by the urinary bladder wall (0.135 ± 0.046 mGy/mBq) and the kidneys (0.070 ± 0.018 mGy/MBq), in accordance with the expected SSTR-specific uptake in the spleen and renal excretion of the tracer. The effective dose was 22.4 ± 4.4 μSv/MBq. The physiologic uptake pattern of [18 F]AlF-OC was comparable to [68 Ga]Ga-DOTATATE. Mean tumour SUVmax was lower for [18 F]AlF-OC (12.3 ± 6.5 at 2 h post-injection vs. 18.3 ± 9.5; p = 0.03). However, no significant differences were found in TBR (9.8 ± 6.7 at 2 h post-injection vs. 13.6 ± 11.8; p = 0.35). DR was high and comparable for both tracers (86.0% for [68 Ga]Ga-DOTATATE vs. 90.1% for [18 F]AlF-OC at 2 h post-injection; p = 0.68). Conclusion: [18 F]AlF-OC shows favourable kinetic and imaging characteristics in patients that warrant further head-to-head comparison to validate [18 F]AlF-OC as a fluorine-18-labelled alternative for gallium-68-labelled SSA clinical PET. Trial registration: Clinicaltrials.gov: NCT03883776, EudraCT: 2018-002827-40 [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.
- Author
-
Van Weehaeghe, Donatienne, Devrome, Martijn, Schramm, Georg, De Vocht, Joke, Deckers, Wies, Baete, Kristof, Van Damme, Philip, Koole, Michel, and Van Laere, Koen
- Subjects
SPINAL muscular atrophy ,MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,THORACIC vertebrae ,BRAIN metabolism ,CERVICAL vertebrae - Abstract
Purpose: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with on average a 1-year delay between symptom onset and diagnosis. Studies have demonstrated the value of [
18 F]-FDG PET as a sensitive diagnostic biomarker, but the discriminatory potential to differentiate ALS from patients with symptoms mimicking ALS has not been investigated. We investigated the combination of brain and spine [18 F]-FDG PET-CT for differential diagnosis between ALS and ALS mimics in a real-life clinical diagnostic setting. Methods: Patients with a suspected diagnosis of ALS (n = 98; 64.8 ± 11 years; 61 M) underwent brain and spine [18 F]-FDG PET-CT scans. In 62 patients, ALS diagnosis was confirmed (67.8 ± 10 years; 35 M) after longitudinal follow-up (average 18.1 ± 8.4 months). In 23 patients, another disease was diagnosed (ALS mimics, 60.9 ± 12.9 years; 17 M) and 13 had a variant motor neuron disease, primary lateral sclerosis (PLS; n = 4; 53.6 ± 2.5 years; 2 M) and progressive muscular atrophy (PMA; n = 9; 58.4 ± 7.3 years; 7 M). Spine metabolism was determined after manual and automated segmentation. VOI- and voxel-based comparisons were performed. Moreover, a support vector machine (SVM) approach was applied to investigate the discriminative power of regional brain metabolism, spine metabolism and the combination of both. Results: Brain metabolism was very similar between ALS mimics and ALS, whereas cervical and thoracic spine metabolism was significantly different (in standardised uptake values; cervical: ALS 2.1 ± 0.5, ALS mimics 1.9 ± 0.4; thoracic: ALS 1.8 ± 0.3, ALS mimics 1.5 ± 0.3). As both brain and spine metabolisms were very similar between ALS mimics and PLS/PMA, groups were pooled for accuracy analyses. Mean discrimination accuracy was 65.4%, 80.0% and 81.5%, using only brain metabolism, using spine metabolism and using both, respectively. Conclusion: The combination of brain and spine FDG PET-CT with SVM classification is useful as discriminative biomarker between ALS and ALS mimics in a real-life clinical setting. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Interhemispheric metabolic asymmetries in patients with anti-NMDA receptor encephalitis.
- Author
-
Serrien, Anouk, Cleeren, Evy, Van Laere, Koen, Goffin, Karolien, and Van Paesschen, Wim
- Published
- 2021
- Full Text
- View/download PDF
24. Direct prospective comparison of 18F-FDG PET and arterial spin labelling MR using simultaneous PET/MR in patients referred for diagnosis of dementia.
- Author
-
Ceccarini, Jenny, Bourgeois, Sophie, Van Weehaeghe, Donatienne, Goffin, Karolien, Vandenberghe, Rik, Vandenbulcke, Mathieu, Sunaert, Stefan, and Van Laere, Koen
- Subjects
SPIN labels ,LEWY body dementia ,FLUORODEOXYGLUCOSE F18 ,FRONTOTEMPORAL dementia ,DEMENTIA ,DRUG labeling ,MAGNETIC resonance angiography ,CRYSTALLIZATION - Abstract
Purpose:
18 F-FDG PET is routinely used as an imaging marker in the early and differential diagnosis of dementing disorders and has incremental value over the clinical neurological and neuropsychological evaluation. Perfusion MR imaging by means of arterial spin labelling (ASL) is an alternative modality to indirectly measure neuronal functioning and could be used as complement measurement in a single MR session in the workup of dementia. Using simultaneous PET-MR, we performed a direct head-to-head comparison between enhanced multiplane tagging ASL (eASL) and18 F-FDG PET in a true clinical context of subjects referred for suspicion of neurodegenerative dementia. Methods: Twenty-seven patients underwent a 20-min18 F-FDG PET/MR and simultaneously acquired eASL on a GE Signa PET/MR. Data were compared with 30 screened age- and gender-matched healthy controls. Both integral eASL and18 F-FDG datasets were analysed visually by two readers unaware of the final clinical diagnosis, either in normal/abnormal classes, or full differential diagnosis (normal, Alzheimer type dementia [AD], dementia with Lewy Bodies [LBD], frontotemporal dementia [FTD] or other). Reader confidence was assessed with a rating scale (range 1–4). Data were also analysed semiquantitatively by VOI and voxel-based analyses. Results: The ground truth diagnosis for the patient group resulted in 14 patients with a neurodegenerative cognitive disorder (AD, FTD, LBD) and 13 patients with no arguments for an underlying neurodegenerative cause. Visual analysis resulted in equal specificity (0.70) for differentiating normal and abnormal cases between the two modalities, but in a higher sensitivity (0.93), confidence rating (0.64) and interobserver agreement for18 F-FDG PET compared with eASL. The same was true for assigning a specific differential diagnosis (sensitivity: and 0.39 for18 F-FDG PET and eASL, respectively). Semiquantitative analyses revealed prototypical patterns for AD and FTD, with both higher volumes of abnormality and intensity differences on18 F-FDG PET. Conclusion: In a direct head-to-head comparison on a simultaneous GE Signa PET/MR,18 F-FDG PET performed better compared with ASL in terms of sensitivity and reader confidence, as well as volume and intensity of abnormalities. However, using pure semiquantitative analysis, similar diagnostic accuracy between the two modalities was obtained. Therefore, ASL may still serve as complement to neuroreceptor or protein deposition PET studies when a single simultaneous investigation is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
25. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients.
- Author
-
Schaeverbeke, Jolien, Celen, Sofie, Cornelis, Julie, Ronisz, Alicja, Serdons, Kim, Van Laere, Koen, Thal, Dietmar Rudolf, Tousseyn, Thomas, Bormans, Guy, and Vandenberghe, Rik
- Subjects
APHASIC persons ,FRONTOTEMPORAL lobar degeneration ,ALZHEIMER'S disease ,FRONTOTEMPORAL dementia ,TEMPORAL lobe - Abstract
Purpose: In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic variant primary progressive aphasia (SV PPA) has consistently been reported. This is unexpected as the majority of these patients have frontotemporal lobar degeneration TDP (FTLD-TDP). Methods: We conducted an in vitro [
18 F]AV1451 autoradiography binding study in five cases with a clinical diagnosis of SV PPA constituting the range of pathologies (i.e., three FTLD-TDP, one Alzheimer's disease (AD), and one Pick's disease (PiD)). Binding was compared with two controls without neurodegeneration, two typical AD, one corticobasal syndrome with underlying AD, and one frontotemporal dementia behavioral variant with FTLD-TDP. The effect of blocking with the authentic reference material and with the MAO-B inhibitor deprenyl was assessed. Immunohistochemistry was performed on adjacent cryosections. Results: Absence of specific [18 F]AV1451 binding was observed for all three SV PPA FTLD-TDP cases. The absence of binding in controls as well as the successful blocking with authentic AV1451 in cases with tauopathy demonstrated specificity of the [18 F]AV1451 signal for tau. The specific [18 F]AV1451 binding was highest in AD, followed by PiD. This binding colocalized with the respective tau lesions and could not be blocked by deprenyl. Similar pilot findings were obtained with [18 F]THK5351. Conclusion: In vitro autoradiography showed no [18 F]AV1451 binding in SV PPA due to FTLD-TDP, while specific binding was present in SV PPA due to AD and PiD. The discrepancy between in vitro and in vivo findings remains to be explained. The discordance is not related to [18 F]AV1451 idiosyncrasies as [18 F]THK5351 findings were similar. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease.
- Author
-
Delva, Aline, Van Weehaeghe, Donatienne, van Aalst, June, Ceccarini, Jenny, Koole, Michel, Baete, Kristof, Nuyts, Johan, Vandenberghe, Wim, and Van Laere, Koen
- Subjects
PARKINSON'S disease ,DISCRIMINANT analysis ,PHARMACOKINETICS - Abstract
Rationale: Dopamine transporter (DAT) imaging is an important adjunct in the diagnostic workup of patients with Parkinsonism.
18 F-FE-PE2I is a suitable PET radioligand for DAT quantification and imaging with good pharmacokinetics. The aim of this study was to determine a clinical optimal simplified reference tissue-based image acquisition protocol and to compare the discriminatory value and effect size for18 F-FE-PE2I to that for123 I-FP-CIT scan currently used in clinical practice. Methods: Nine patients with early Parkinson's disease (PD, 64.3 ± 6.8 years, 3M), who had previously undergone a123 I-FP-CIT scan as part of their diagnostic workup, and 34 healthy volunteers (HV, 47.7 ± 16.8 years, 13M) underwent a 60-min dynamic18 F-FE-PE2I PET-MR scan on a GE Signa 3T PET-MR. Based on dynamic data and MR-based VOI delineation, BPND , semi-quantitative uptake ratio and SUVR[t1–t2] images were calculated using either occipital cortex or cerebellum as reference region. For start-and-end time of the SUVR interval, three time frames [t1 –t2 ] were investigated: [15–40] min, [40–60] min, and [50–60] min postinjection. Data for putamen (PUT) and caudate nucleus-putamen ratio (CPR) were compared in terms of quantification bias versus BPND and discriminative power. Results: Using occipital cortex as reference region resulted in smaller bias of SUVR with respect to BPND + 1 and higher correlation between SUVR and BPND + 1 compared with using cerebellum, irrespective of SUVR [t1 –t2 ] interval. Smallest bias was observed with the [15–40]-min time window, in accordance with previous literature. The correlation between BPND + 1 and SUVR was slightly better for the late time windows. Discriminant analysis between PD and HV using both PUT and CPR SUVRs showed an accuracy of ≥ 90%, for both reference regions and all studied time windows. Semi-quantitative123 I-FP-CIT and18 F-FE-PE2I values and relative decrease in the striatum for patients were highly correlated, with a higher effect size for18 F-FE-PE2I for PUT and CPR SUVR. Conclusion:18 F-FE-PE2I is a suitable radioligand for in vivo DAT imaging with high discriminative power between early PD and healthy controls. Whereas a [15–40]-min window has lowest bias with respect to BPND , a [50–60]-min time window at pseudoequilibrium can be advocated in terms of clinical feasibility with optimal discriminative power. The occipital cortex may be slightly preferable as reference region because of the higher time stability, stronger correlation of SUVR with BPND + 1, and lower bias. Moreover, the data suggest that the diagnostic accuracy of a 10-min static18 F-FE-PE2I scan is non-inferior compared with123 I-FP-CIT scan used in standard clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
27. Long-term Ashtanga yoga practice decreases medial temporal and brainstem glucose metabolism in relation to years of experience.
- Author
-
van Aalst, June, Ceccarini, Jenny, Schramm, Georg, Van Weehaeghe, Donatienne, Rezaei, Ahmadreza, Demyttenaere, Koen, Sunaert, Stefan, and Van Laere, Koen
- Subjects
GLUCOSE metabolism ,YOGA ,DIFFUSION tensor imaging ,POSITRON emission tomography ,EXERCISE ,BRAIN stem - Abstract
Background: Yoga is increasingly popular worldwide with several physical and mental benefits, but the underlying neurobiology remains unclear. Whereas many studies have focused on pure meditational aspects, the triad of yoga includes meditation, postures, and breathing. We conducted a cross-sectional study comparing experienced yoga practitioners to yoga-naive healthy subjects using a multiparametric 2 × 2 design with simultaneous positron emission tomography/magnetic resonance (PET/MR) imaging. Methods:
18 F-FDG PET, morphometric and diffusion tensor imaging, resting state fMRI, and MR spectroscopy were acquired in 10 experienced (4.8 ± 2.3 years of regular yoga experience) yoga practitioners and 15 matched controls in rest and after a single practice (yoga practice and physical exercise, respectively). Results: In rest, decreased regional glucose metabolism in the medial temporal cortex, striatum, and brainstem was observed in yoga practitioners compared to controls (p < 0.0001), with a significant inverse correlation of resting parahippocampal and brainstem metabolism with years of regular yoga practice (ρ < − 0.63, p < 0.05). A single yoga practice resulted in significant hypermetabolism in the cerebellum (p < 0.0001). None of the MR measures differed, both at rest and after intervention. Conclusions: Experienced yoga practitioners show regional long-term decreases in glucose metabolism related to years of practice. To elucidate a potential causality, a prospective longitudinal study in yoga-naive individuals is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
28. Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue.
- Author
-
Mertens, Nathalie, Maguire, Ralph Paul, Serdons, Kim, Lacroix, Brigitte, Mercier, Joel, Sciberras, David, Van Laere, Koen, and Koole, Michel
- Subjects
WHITE matter (Nerve tissue) ,POSITRON emission tomography ,SYNAPTIC vesicles ,METABOLITE analysis ,RANK correlation (Statistics) ,TISSUES ,DIFFUSION tensor imaging ,RESEARCH methodology evaluation - Abstract
Purpose: The aim of this study was to evaluate different non-invasive methods for generating (R)-1-((3-([11C]methyl)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) ([11C]UCB-J) parametric maps using white matter (centrum semi-ovale-SO) as reference tissue.Procedures: Ten healthy volunteers (8 M/2F; age 27.6 ± 10.0 years) underwent a 90-min dynamic [11C]UCB-J positron emission tomography (PET) scan with full arterial blood sampling and metabolite analysis before and after administration of a novel chemical entity with high affinity for presynaptic synaptic vesicle glycoprotein 2A (SV2A). A simplified reference tissue model (SRTM2), multilinear reference tissue model (MRTM2), and reference Logan graphical analysis (rLGA) were used to generate binding potential maps using SO as reference tissue (BPSO). Shorter dynamic acquisitions down to 50 min were also considered. In addition, standard uptake value ratios (SUVR) relative to SO were evaluated for three post-injection intervals (SUVRSO,40-70min, SUVRSO,50-80min, and SUVRSO,60-90min respectively). Regional parametric BPSO + 1 and SUVRSO were compared with regional distribution volume ratios of a 1-tissue compartment model (1TCM DVRSO) using Spearman correlation and Bland-Altman analysis.Results: For all methods, highly significant correlations were found between regional, parametric BPSO + 1 (r = [0.63;0.96]) or SUVRSO (r = [0.90;0.91]) estimates and regional 1TCM DVRSO. For a 90-min dynamic scan, parametric SRTM2 and MRTM2 values presented similar small bias and variability (- 3.0 ± 2.9 % for baseline SRTM2) and outperformed rLGA (- 10.0 ± 5.3 % for baseline rLGA). Reducing the dynamic acquisition to 60 min had limited impact on the bias and variability of parametric SRTM2 BPSO estimates (- 1.0 ± 9.9 % for baseline SRTM2) while a higher variability (- 1.83 ± 10.8 %) for baseline MRTM2 was observed for shorter acquisition times. Both SUVRSO,60-90min and SUVRSO,50-80min showed similar small bias and variability (- 2.8 ± 4.6 % bias for baseline SUVRSO,60-90min).Conclusion: SRTM2 is the preferred method for a voxelwise analysis of dynamic [11C]UCB-J PET using SO as reference tissue, while reducing the dynamic acquisition to 60 min has limited impact on [11C]UCB-J BPSO parametric maps. For a static PET protocol, both SUVRSO,60-90min and SUVRSO,50-80min images are an excellent proxy for [11C]UCB-J BPSO parametric maps. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.
- Author
-
Koole, Michel, Lohith, Talakad G., Valentine, John L., Bennacef, Idriss, Declercq, Ruben, Reynders, Tom, Riffel, Kerry, Celen, Sofie, Serdons, Kim, Bormans, Guy, Ferry-Martin, Sandrine, Laroque, Philippe, Walji, Abbas, Hostetler, Eric D., Briscoe, Richard J., de Hoon, Jan, Sur, Cyrille, Van Laere, Koen, and Struyk, Arie
- Subjects
POSITRON emission tomography ,NEUROFIBRILLARY tangles ,RADIATION dosimetry ,INTRAVENOUS injections ,DIAGNOSTIC imaging ,BRAIN imaging ,RESEARCH ,NEURONS ,ALZHEIMER'S disease ,HUMAN research subjects ,RADIATION measurements ,ANIMAL experimentation ,RESEARCH methodology ,ISOQUINOLINE ,RADIOISOTOPES ,EVALUATION research ,MEDICAL cooperation ,FLUORINE isotopes ,RATS ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,PATIENT safety - Abstract
Purpose: [18F]MK-6240 is a selective, high-affinity positron emission tomography tracer for imaging neurofibrillary tangles, a key pathological signature that correlates with cognitive decline in Alzheimer disease. This report provides safety information from preclinical toxicology studies and first-in-human whole-body biodistribution and dosimetry studies of [18F]MK-6240 for its potential application in human brain imaging studies.Procedures: MK-6240 was administered intravenously (IV) in a 7-day rat toxicity study at × 50, × 100, and × 1000 dose margins relative to projected highest clinical dose of 0.333 μg/kg. The IV formulation of MK-6240 for clinical use and the formulation used in the 7-day rat toxicity study was tested for hemolysis potential in human and Wistar rat whole blood. Sequential whole-body positron emission tomography scans were performed in three healthy young subjects after IV bolus injection of 180 ± 0.3 MBq [18F]MK-6240 to characterize organ biodistribution and estimate whole-body radiation exposure (effective dose).Results: MK-6240 administered IV in a 7-day rat toxicity study did not show any test article-related changes. The no-observed-adverse-effect level in rats was ≥ 333 μg/kg/day which provides a margin 1000-fold over an anticipated maximum clinical dose of 0.333 μg/kg. Additionally, the MK-6240 formulation was not hemolytic in human or Wistar rat blood. [18F]MK-6240 activity was widely distributed to the brain and the rest of the body, with organ absorbed doses largest for the gall bladder (202 μGy/MBq). The average (±SD) effective dose was 29.4 ± 0.6 μSv/MBq, which is in the typical range for F-18 radiolabeled ligands.Conclusions: Microdoses of [18F]MK-6240 are safe for clinical positron emission tomography imaging studies. Single IV administration of 185 MBq (5 mCi) [18F]MK-6240 is anticipated to result in a total human effective dose of 5.4 mSv and thus allows multiple positron emission tomography scans of the same subject per year. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
30. Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.
- Author
-
Ceccarini, Jenny, Casteels, Cindy, Ahmad, Rawaha, Crabbé, Melissa, Van de Vliet, Laura, Vanhaute, Heleen, Vandenbulcke, Mathieu, Vandenberghe, Wim, and Van Laere, Koen
- Subjects
VOXEL-based morphometry ,PARKINSON'S disease ,CANNABINOID receptors ,MILD cognitive impairment ,MOTOR cortex ,EPISODIC memory ,MAGNETIC resonance imaging - Abstract
Purpose: The endocannabinoid system plays a regulatory role in a number of physiological functions, including motor control but also mood, emotion, and cognition. A number of preclinical studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CB
1 R) may improve motor symptoms and components of cognitive processing. However, the relation between CB1 R, cognitive decline and behavioral symptoms has not been investigated in PD patients so far. The aim of this study was to examine whether CB1 R availability is associated with measures of cognitive and behavioral function in PD patients. Methods: Thirty-eight PD patients and ten age- and gender-matched controls underwent a [18 F]MK-9470 PET scan to assess CB1 R availability, as well as volumetric MR imaging. Neuropsychological symptoms were evaluated using an extensive cognitive and behavioral battery covering the five cognitive domains, depression, anxiety, apathy, and psychiatric complications, and were correlated to CB1 R availability using vowel-wise regression analysis (P < 0.05, corrected for familywise error). Results: PD patients with poorer performance in episodic memory, executive functioning, speed and mental flexibility (range P 0.003–0.03) showed lower CB1 R availability in predominantly the midcingulate cortex and middle to superior frontal gyrus (Tpeak-level > 4.0). Also, PD patients with more severe visuospatial dysfunction showed decreased CB1 R availability in the precuneus, midcingulate, supplementary motor cortex, inferior orbitofrontal gyrus and thalamus (Tpeak-level = 5.5). These correlations were not related to cortical gray matter atrophy. No relationship was found between CB1 R availability and mood or behavioral symptom scores. Conclusions: Decreased CB1 R availability in the prefrontal and midcingulate cortex in PD patients is strongly correlated with disturbances in executive functioning, episodic memory, and visuospatial functioning. Further investigation of regional CB1R expression in groups of PD patients with mild cognitive impairment or dementia is warranted in order to further investigate the role of CB1R expression in different levels of cognitive impairment in PD. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
31. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers
- Author
-
Van Weehaeghe, Donatienne, Koole, Michel, Schmidt, Mark E., Deman, Stephanie, Jacobs, Andreas H., Souche, Erika, Serdons, Kim, Sunaert, Stefan, Bormans, Guy, Vandenberghe, Wim, and Van Laere, Koen
- Subjects
PARKINSON'S disease ,RADIATION dosimetry ,PHARMACOKINETICS ,FLUORODEOXYGLUCOSE F18 ,DOPAMINERGIC neurons ,ABSORBED dose ,ION channels ,VOLUNTEERS - Abstract
Purpose: The P2X7 receptor (P2X7R) is an ATP-gated ion channel predominantly expressed on activated microglia and is important in neurodegenerative diseases including Parkinson's disease (PD). In this first-in-human study, we investigated [
11 C]JNJ54173717 ([11 C]JNJ717), a selective P2X7R tracer, in healthy volunteers (HV) and PD patients. Biodistribution, dosimetry, kinetic modelling and short-term test–retest variation (TRV), as well as possible genotype effects, were investigated. Methods: Biodistribution and radiation dosimetry studies were performed in three HV (mean age 30 ± 2 years, two women) using whole-body PET/CT. The most appropriate kinetic model was determined in 11 HV (mean age 62 ± 10 years, six women) and 10 PD patients (mean age 64 ± 8 years, three women; mean UPDRS motor score 21 ± 8) using 90-min dynamic simultaneous PET/MR scans. The total volume of distribution (VT ) was calculated using a one-tissue and a two-tissue compartment model (1TCM, 2TCM) and Logan graphical analysis, and its time stability was assessed. Seven subjects underwent retest scans (mean age 60 ± 13 years, four HV, one woman). A group analysis was performed to compare PD patients and HV. Finally, 13 exons of P2X7R were genotyped in all subjects included in the second part of the study. Results: The mean effective dose was 4.47 ± 0.32 μSv/MBq, with the highest absorbed doses to the gallbladder, liver and small intestine. A reversible 2TCM was the most appropriate kinetic model with relatively homogeneous VT values in the grey and white matter. Average VT values were 3.4 ± 0.8 in HV and 3.3 ± 0.7 in PD patients, with no significant difference between the groups, but a possible genotype effect (rs3751143) was identified which can affect VT . Average TRV was 10–15%. The stability of VT over time allowed a reduction in scan time to 70 min. Conclusion: [11 C]JNJ717 is safe and suitable for quantifying P2X7R expression in human brain. In this pilot study, no significant differences in P2X7R binding were found between HV and PD patients. The results also suggest that genotype effects need to be incorporated in future P2X7R PET analyses. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
32. Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue.
- Author
-
Koole, Michel, van Aalst, June, Devrome, Martijn, Mertens, Nathalie, Serdons, Kim, Van Laere, Koen, Lacroix, Brigitte, Mercier, Joel, Sciberras, David, and Maguire, Paul
- Subjects
GLYCOPROTEINS ,BRAIN ,GENE expression ,WHITE matter (Nerve tissue) ,BLOOD sampling ,POSITRON emission ,DIAGNOSTIC imaging - Abstract
Purpose: A [
11 C]UCB-J blocking study was performed in healthy volunteers to validate simplified, non-invasive measures for quantifying presynaptic SV2A expression using subcortical white matter as reference tissue.Methods: Ninety minutes dynamic [11 C]UCB-J PET scanning with arterial blood sampling was performed in 10 healthy volunteers (8 M/2F; age 27.6 ± 10.0 yrs), before and after administration of a novel chemical entity with selective affinity for SV2A. The centrum semi-ovale (SO) was validated as reference region by comparing baseline and post treatment distribution volume (VT ). Using SO as reference tissue, Binding Potential (BPSO ) using a Simplified Reference Tissue Model (SRTM, down to 60 min acquisition) and Standardized Uptake Value Ratios (60-90 min post injection - SUVRSO,60-90min ) were compared with regional distribution volume ratios (DVR). Next, SV2A occupancy values based on SRTM BPSO and SUVRSO,60-90min were compared to occupancy estimates using regional VT values and a Lassen plot.Results: After pretreatment, regional VT values were reduced significantly except for SO. Highly significant correlations were found between DVR, SRTM BPSO and SUVRSO,60-90min . Compared to DVR, baseline SRTM BPSO showed a small bias (≤ 6.1%) with lower precision for shorter acquisition times, while SUVRSO,60-90min showed 3.5% bias with similar precision. Differences between SV2A occupancy values based on SUVRSO,60-90min and occupancy estimates using VT and a Lassen plot were small but significant, while negligible bias was found for SRTM based occupancy estimates (at least 70 min acquisition).Conclusion: This [11 C]UCB-J blocking study validated SO as a suitable reference region for non-invasive quantification of SV2A availability and drug occupancy in the human brain. Accurate quantification can be achieved by using either SUVRSO,60-90min with a 60-90 min PET acquisition or SRTM BPSO with at least 70 min dynamic PET acquisition. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
33. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants.
- Author
-
Meersmans, Karen, Schaeverbeke, Jolien, Evenepoel, Charlotte, Gabel, Silvy, Adamczuk, Kate, Dupont, Patrick, Vandenberghe, Rik, Bruffaerts, Rose, Peeters, Ronald, Van Laere, Koen, Declercq, Lieven, Bormans, Guy, Koole, Michel, Dries, Eva, Van Bouwel, Karen, Sieben, Anne, and Pijnenburg, Yolande
- Subjects
APHASIA ,DNA-binding proteins ,POSITRON emission tomography ,SPEECH disorders ,TAU proteins - Abstract
Purpose: To assess the binding of the PET tracer [
18 F]THK5351 in patients with different primary progressive aphasia (PPA) variants and its correlation with clinical deficits. The majority of patients with nonfluent variant (NFV) and logopenic variant (LV) PPA have underlying tauopathy of the frontotemporal lobar or Alzheimer disease type, respectively, while patients with the semantic variant (SV) have predominantly transactive response DNA binding protein 43-kDa pathology.Methods: The study included 20 PPA patients consecutively recruited through a memory clinic (12 NFV, 5 SV, 3 LV), and 20 healthy controls. All participants received an extensive neurolinguistic assessment, magnetic resonance imaging and amyloid biomarker tests. [18 F]THK5351 binding patterns were assessed on standardized uptake value ratio (SUVR) images with the cerebellar grey matter as the reference using statistical parametric mapping. Whole-brain voxel-wise regression analysis was performed to evaluate the association between [18 F]THK5351 SUVR images and neurolinguistic scores. Analyses were performed with and without partial volume correction.Results: Patients with NFV showed increased binding in the supplementary motor area, left premotor cortex, thalamus, basal ganglia and midbrain compared with controls and patients with SV. Patients with SV had increased binding in the temporal lobes bilaterally and in the right ventromedial frontal cortex compared with controls and patients with NFV. The whole-brain voxel-wise regression analysis revealed a correlation between agrammatism and motor speech impairment, and [18 F]THK5351 binding in the left supplementary motor area and left postcentral gyrus. Analysis of [18 F]THK5351 scans without partial volume correction revealed similar results.Conclusion: [18 F]THK5351 imaging shows a topography closely matching the anatomical distribution of predicted underlying pathology characteristic of NFV and SV PPA. [18 F]THK5351 binding correlates with the severity of clinical impairment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
34. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour.
- Author
-
Pauwels, Elin, Celen, Sofie, Vandamme, Mathilde, Leysen, William, Baete, Kristof, Bechter, Oliver, Bex, Marie, Serdons, Kim, Van Laere, Koen, Bormans, Guy, and Deroose, Christophe M.
- Subjects
COLLIMATORS ,CARDIAC radionuclide imaging ,NORADRENALINE ,SINGLE-photon emission computed tomography ,RADIONUCLIDE imaging ,POSITRON emission tomography ,TUMORS - Abstract
Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter-expressing tumour Moreover, if neural crest tumour patients are considered for peptide receptor radionuclide therapy, addition of norepinephrine transporter imaging to the pre-therapeutic work-up allows evaluating whether [ SP 131 sp I]MIBG or a combination treatment may increase therapeutic efficacy. [ SP 18 sp F]MFBG is a promising clinical PET alternative for [ SP 123 sp I]MIBG, offering improved sensitivity, same-day imaging and the possibility of PET/MR imaging, as a one-stop-shop for patients with norepinephrine transporter-expressing tumours. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
35. Patient Safety Considerations for Combined PET/MR Imaging.
- Author
-
Koole, Michel, Baete, Kristof, Porters, Kwinten, Peeters, Ronald, and van Laere, Koen
- Published
- 2017
- Full Text
- View/download PDF
36. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.
- Author
-
Nobili, Flavio, Festari, Cristina, Altomare, Daniele, Agosta, Federica, Orini, Stefania, Van Laere, Koen, Arbizu, Javier, Bouwman, Femke, Drzezga, Alexander, Nestor, Peter, Walker, Zuzana, Boccardi, Marina, and For the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
- Subjects
NEURODEGENERATION ,FLUORODEOXYGLUCOSE F18 ,POSITRON emission tomography ,BRAIN imaging ,DIAGNOSIS of dementia ,DIAGNOSIS - Abstract
Purpose: To review literature until November 2015 and reach a consensus on whether automatic semi-quantification of brain FDG-PET is useful in the clinical setting for neurodegenerative disorders.Methods: A literature search was conducted in Medline, Embase, and Google Scholar. Papers were selected with a lower limit of 30 patients (no limits with autopsy confirmation). Consensus recommendations were developed through a Delphi procedure, based on the expertise of panelists, who were also informed about the availability and quality of evidence, assessed by an independent methodology team.Results: Critical outcomes were available in nine among the 17 papers initially selected. Only three papers performed a direct comparison between visual and automated assessment and quantified the incremental value provided by the latter. Sensitivity between visual and automatic analysis is similar but automatic assessment generally improves specificity and marginally accuracy. Also, automated assessment increases diagnostic confidence. As expected, performance of visual analysis is reported to depend on the expertise of readers.Conclusions: Tools for semi-quantitative evaluation are recommended to assist the nuclear medicine physician in reporting brain FDG-PET pattern in neurodegenerative conditions. However, heterogeneity, complexity, and drawbacks of these tools should be known by users to avoid misinterpretation. Head-to-head comparisons and an effort to harmonize procedures are encouraged. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [I]FP-CIT SPECT imaging.
- Author
-
Dickson, John, Tossici-Bolt, Livia, Sera, Terez, Booij, Jan, Ziebell, Morten, Morbelli, Silvia, Assenbaum-Nan, Susanne, Borght, Thierry, Pagani, Marco, Kapucu, Ozlem, Hesse, Swen, Van Laere, Koen, Darcourt, Jacques, Varrone, Andrea, and Tatsch, Klaus
- Subjects
SINGLE-photon emission computed tomography ,DIAGNOSTIC imaging ,DOPAMINE receptors ,IMAGE reconstruction ,MEDICAL databases ,FOLLOW-up studies (Medicine) - Abstract
Background: The use of a normal database for [I]FP-CIT SPECT imaging has been found to be helpful for cases which are difficult to interpret by visual assessment alone, and to improve reproducibility in scan interpretation. The aim of this study was to assess whether the use of different tomographic reconstructions affects the performance of a normal [I]FP-CIT SPECT database and also whether systems benefit from a system characterisation before a database is used. Seventy-seven [I]FP-CIT SPECT studies from two sites and with 3-year clinical follow-up were assessed quantitatively for scan normality using the ENC-DAT normal database obtained in well-documented healthy subjects. Patient and normal data were reconstructed with iterative reconstruction with correction for attenuation, scatter and septal penetration (ACSC), the same reconstruction without corrections (IRNC), and filtered back-projection (FBP) with data quantified using small volume-of-interest (VOI) (BRASS) and large VOI (Southampton) analysis methods. Test performance was assessed with and without system characterisation, using receiver operating characteristics (ROC) analysis for age-independent data and using sensitivity/specificity analysis with age-matched normal values. The clinical diagnosis at follow-up was used as the standard of truth. Results: There were no significant differences in the age-independent quantitative assessment of scan normality across reconstructions, system characterisation and quantitative methods (ROC AUC 0.866-0.924). With BRASS quantification, there were no significant differences between the values of sensitivity (67.4-83.7%) or specificity (79.4-91.2%) across all reconstruction and calibration strategies. However, the Southampton method showed significant differences in sensitivity between ACSC (90.7%) vs IRNC (76.7%) and FBP (67.4%) reconstructions with calibration. Sensitivity using ACSC reconstruction with this method was also significantly better with calibration than without calibration (65.1%). Specificity using the Southampton method was unchanged across reconstruction and calibration choices (82.4-88.2%). Conclusions: The ability of a normal [I]FP-CIT SPECT database to assess clinical scan normality is equivalent across all reconstruction, system characterisation, and quantification strategies using BRASS quantification. However, when using the Southampton quantification method, performance is sensitive to the reconstruction and calibration strategy used. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.
- Author
-
Ooms, Maarten, Celen, Sofie, De Hoogt, Ronald, Lenaerts, Ilse, Liebregts, Johnny, Vanhoof, Greet, Langlois, Xavier, Postnov, Andrey, Koole, Michel, Verbruggen, Alfons, Van Laere, Koen, and Bormans, Guy
- Subjects
PHOSPHODIESTERASES ,DOPAMINE analysis ,POSITRON emission tomography ,BRAIN imaging ,NEUROBEHAVIORAL disorders - Abstract
Background: Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. Here, we used [F]JNJ42259152 PET to measure changes in PDE10A availability, secondary to pharmacological alterations in DA release and to investigate whether these are D- or D-receptor driven. Results: Acute treatment of rats using D-amphetamine (5 mg, s.c. and 1 mg/kg i.v.) did not result in a significant change in PDE10A BP compared to baseline conditions. 5-day D-amphetamine treatment (5 mg/kg, s.c.) increased striatal PDE10A BP compared to the baseline (+24 %, p = 0.03). Treatment with the selective D2 antagonist SCH23390 (1 mg/kg) and D-amphetamine decreased PDE10A binding (-22 %, p = 0.03). Treatment with only SCH23390 further decreased PDE10A binding (-26 %, p = 0.03). No significant alterations in PDE10A mRNA levels were observed. Conclusions: Repeated D-amphetamine treatment significantly increased PDE10A binding, which is not observed upon selective D receptor blocking. This study suggests a potential pharmacological interaction between PDE10A enzymes and drugs modifying DA neurotransmission. Therefore, PDE10A binding in patients with neuropsychiatric disorders might be modulated by chronic DA-related treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Amyloid imaging in cognitively normal older adults: comparison between F-flutemetamol and C-Pittsburgh compound B.
- Author
-
Adamczuk, Katarzyna, Schaeverbeke, Jolien, Nelissen, Natalie, Neyens, Veerle, Vandenbulcke, Mathieu, Goffin, Karolien, Lilja, Johan, Hilven, Kelly, Dupont, Patrick, Van Laere, Koen, and Vandenberghe, Rik
- Subjects
ALZHEIMER'S disease ,BIOMARKERS ,DRUG development ,RANK correlation (Statistics) ,RADIOPHARMACEUTICALS - Abstract
Purpose: Preclinical, or asymptomatic, Alzheimer's disease (AD) refers to the presence of positive AD biomarkers in the absence of cognitive deficits. This research concept is being applied to define target populations for clinical drug development. In a prospective community-recruited cohort of cognitively intact older adults, we compared two amyloid imaging markers within subjects: F-flutemetamol and C-Pittsburgh compound B (PIB). Methods: In 32 community-recruited cognitively intact older adults aged between 65 and 80 years, we determined the concordance between binary classification based on F-flutemetamol versus C-PIB according to semiquantitative assessment (standardized uptake value ratio in composite cortical volume, SUVR) and, alternatively, according to visual reads. We also determined the correlation between F-flutemetamol and C-PIB SUVR and evaluated how this was affected by the reference region chosen (cerebellar grey matter versus pons) and the use of partial volume correction (PVC) in this population. Results: Binary classification based on semiquantitative assessment was concordant between F-flutemetamol and C-PIB in 94 % of cases. Concordance of blinded binary visual reads between tracers was 84 %. The Spearman correlation between F-flutemetamol and C-PIB SUVR with cerebellar grey matter as reference region was 0.84, with a slope of 0.98. Correlations in neocortical regions were significantly lower with the pons as reference region. PVC improved the correlation in striatum and medial temporal cortex. Conclusion: For the definition of preclinical AD based on F-flutemetamol, concordance with C-PIB was highest using semiquantitative assessment with cerebellar grey matter as reference region. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Applications of Small-Animal Imaging in Neurology and Psychiatry.
- Author
-
Casteels, Cindy, Zaidi, Habib, and Van Laere, Koen
- Published
- 2014
- Full Text
- View/download PDF
41. PET Quantification in Neuropsychiatry.
- Author
-
Koole, Michel, Casteels, Cindy, and Van Laere, Koen
- Abstract
PET quantification in neuropsychiatry focuses on the quantification of dynamic brain PET data. Starting from the basics of dynamic PET imaging, different methodologies are presented to extract time-dependent activity concentration for specific brain regions, both manually and automatically. The latter methodology uses predefined VOI templates and has the advantage of being operator independent. Once time-activity curves are available for the brain regions of interest, kinetic modeling is described using different compartmental models. These compartments represent the different states of the radiotracer such as the bound state. This way, the PET signal of specifically tracer can be separated from tracer that is free or nonspecifically bound. In this context, quantitative endpoints such as distribution volume and binding potential are discussed. Next to compartment modeling, graphical analysis techniques for reversible and irreversible tracer kinetics are discussed. These techniques are computational efficient and therefore suitable for creating parametric image data. These parametric image data allow voxel-wise statistical comparison of dynamic PET data. In terms of different options for the input function which is needed for tracer kinetic modeling, we discuss different possibilities including a reference tissue model. Finally, we elaborate on the advantages and limitations of a bolus/constant infusion approach to quantify tracer uptake under steady-state conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. MRI/PET Brain Imaging.
- Author
-
Koole, Michel, Vunckx, Kathleen, Verhaeghe, Jeroen, Van Laere, Koen, and Van Laar, Peter Jan
- Published
- 2014
- Full Text
- View/download PDF
43. SPECT and PET.
- Author
-
Van Paesschen, Wim, Goffin, Karolien, and Van Laere, Koen
- Published
- 2013
- Full Text
- View/download PDF
44. Clinical SPECT and PET for Management of Patients with Refractory Epilepsy.
- Author
-
Van Laere, Koen, Goffin, Karolien, and Van Paesschen, Wim
- Published
- 2012
- Full Text
- View/download PDF
45. Brain Tumor Imaging: European Association of Nuclear Medicine Procedure Guidelines.
- Author
-
Borght, Thierry Vander, Asenbaum, Susanne, Bartenstein, Peter, Halldin, Christer, Kapucu, Özlem, Van Laere, Koen, Varrone, Andrea, and Tatsch, Klaus
- Abstract
These guidelines summarize the views of the European Association of Nuclear Medicine (EANM) Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain tumor imaging using 18-fluoro-2-deoxyglucose-PET (FDG-PET) as well as radiolabeled amino acid analogues SPECT or PET. The aim is to help in achieving a high quality standard of such functional imaging procedures to increase their diagnostic impact in neuroonco-logical practice. The present document is largely based on the EANM guidelines that have been published for FDG-PET (Bartenstein et al. 2002) and labeled amino acid analogues imaging (Vander Borght et al. 2006). It also includes an update in the light of the advances in the PET technology and the introduction of hybrid PET-CT systems, which will be part of the updated guidelines for FDG-PET produced by the ENC. The information provided should be taken in the context of local conditions and regulations. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
46. Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa.
- Author
-
Casteels, Cindy, Gérard, Nathalie, van Kuyck, Kris, Pottel, Lies, Nuttin, Bart, Bormans, Guy, and Van Laere, Koen
- Subjects
POSITRON emission tomography ,CANNABINOID receptors ,LABORATORY rats ,CROSS-sectional method ,FOOD research ,HIPPOCAMPUS (Brain) ,DISEASE research - Abstract
Purpose: Several lines of evidence strongly implicate a dysfunctional endocannabinoid system (ECS) in eating disorders. Using [F]MK-9470 and small animal positron emission tomography (PET), we investigated for the first time cerebral changes in type 1 cannabinoid (CB1) receptor binding in vivo in the activity-based rat model of anorexia (ABA), in comparison to distinct motor- and food-related control conditions and in relation to gender and behavioural variables. Methods: In total, experiments were conducted on 80 Wistar rats (23 male and 57 female). Male rats were assigned to the cross-sectional conditions: ABA ( n = 12) and CONTROL ( n = 11), whereas female rats were divided between two settings: (1) a cross-sectional design using ABA ( n = 13), CONTROL ( n = 9), and two extra control conditions for each of the variables manipulated in ABA, i.e. DIET ( n = 8) and WHEEL ( n = 9), and (2) a longitudinal one using ABA ( n = 10) and CONTROL ( n = 8) studied at baseline, during the model and upon recovery. The ABA group was subjected to food restriction in the presence of a running wheel, the DIET group to food restriction without wheel, the WHEEL group to a normal diet with wheel and CONTROL animals had a normal diet and no running wheel. Parametric CB1 receptor images of each group were spatially normalized to Paxinos space and analysed voxel-wise. Results: In the ABA model, absolute [F]MK-9470 binding was significantly increased in all cortical and subcortical brain areas as compared to control conditions (male +67 %; female >51 %, all p < 6.3×10) that normalized towards baseline values after weight gain. Additionally, relative [F]MK-9470 binding was increased in the hippocampus, inferior colliculus and entorhinal cortex of female ABA (+4.6 %; p < 1.3×10), whereas no regional differences were observed in male subjects. Again, relative [F]MK-9470 binding values normalized upon weight gain. Conclusion: These data point to a widespread transient disturbance of the endocannabinoid transmission, specifically for CB1 receptors in the ABA model. Our data also suggest (1) gender effects on regional CB1 receptor binding in the hippocampus and (2) add further proof to the validity of the ABA model to mimic aspects of human disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study.
- Author
-
Ceccarini, Jenny, Casteels, Cindy, Koole, Michel, Bormans, Guy, and Van Laere, Koen
- Subjects
ALCOHOL drinking ,CANNABINOID receptors ,ETHANOL ,ANANDAMIDE ,POSITRON emission tomography ,ANIMAL models in research - Abstract
Purpose: Recent biochemical and post-mortem evidence suggests involvement of the endocannabinoid system in alcohol drinking behaviour and dependence. Using [F]MK-9470 small-animal PET imaging, our primary objective was to evaluate in vivo type 1 cannabinoid receptor (CB1R) binding changes in rats subjected to several ethanol conditions: (1) at baseline, (2) after acute intraperitoneal administration of ethanol (4 g/kg) or saline, (3) after 7 days of forced chronic ethanol consumption, and (4) after abstinence for 7 and 14 days. Secondly, levels of anandamide (AEA) in the nucleus accumbens (NAcc) were investigated in the same animals using in vivo microdialysis and correlated with the changes in CB1R binding. Methods: In total, 28 male Wistar rats were investigated. Small-animal PET was done on a FOCUS-220 tomograph with [F]MK-9470. Parametric images of [F]MK-9470 binding based on standard uptake values (SUV, as a measure of CB1R binding) were generated. Images were normalized to Paxinos space and analysed voxel-wise using SPM8 ( p = 0.005; k = 200). The AEA content was quantified using HPLC with tandem mass spectrometry detection. Results: Acute ethanol administration increased relative CB1R binding in the NAcc that was positively correlated with the change in AEA levels of that region. In contrast, compared to rats at baseline, AEA levels in the NAcc were not significantly different in rats after chronic ethanol consumption or after a 14-day abstinence period. Chronic ethanol consumption decreased relative CB1R binding in the hippocampus and caudate-putamen, whereas same regions showed increased relative CB1R binding after 7 and 14 days of abstinence compared to the baseline condition. After 7 and 14 days of abstinence, relative CB1R binding additionally decreased in the orbitofrontal cortex. The magnitude of the hippocampal and frontal changes was highly correlated with daily ethanol intake. Conclusion: This study provides in vivo evidence that acute ethanol consumption is associated with enhanced endocannabinoid signalling in the NAcc, indicated by an increased CB1R binding and AEA content. In addition, chronic ethanol exposure leads to regional dysfunctions in CB1R levels, involving the hippocampus and caudate-putamen that are reversible within 2 weeks in this animal model. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
48. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects.
- Author
-
Ahmad, Rawaha, Koole, Michel, Evens, Nele, Serdons, Kim, Verbruggen, Alfons, Bormans, Guy, and Van Laere, Koen
- Abstract
Purpose: The type 2 cannabinoid receptor (CB2R) is part of the human endocannabinoid system and is involved in central and peripheral inflammatory processes. In vivo imaging of the CB2R would allow study of several (neuro)inflammatory disorders. In this study we have investigated the safety and tolerability of [11C]-NE40, a CB2R positron emission tomography (PET) ligand, in healthy human male subjects and determined its biodistribution and radiation dosimetry.Procedure: Six healthy male subjects (age 20-65 years) underwent a dynamic series of nine whole-body PET/CT scans for up to 140 min, after injection of an average bolus of 286 MBq of [11C]-NE40. Organ absorbed and total effective doses were calculated through OLINDA.Results: [11C]-NE40 showed high initial uptake in the spleen and a predominant hepatobiliary excretion. In the brain, rapid uptake and swift washout were seen. Organ absorbed doses were largest for the small intestine and liver, with 15.6 and 11.5 μGy/MBq, respectively. The mean effective dose was 3.64±0.81 μSv/MBq. There were no changes with aging observed. No adverse events were encountered.Conclusions: This first-in-man study of [11C]-NE40 showed an expected biodistribution compatible with lymphoid tissue uptake and appropriate fast brain kinetics in the healthy human brain, underscoring the potential of this tracer for further application in central and peripheral inflammation imaging. The effective dose is within the typical expected range for 11C ligands. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
49. Preclinical evaluation and quantification of [F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain.
- Author
-
Casteels, Cindy, Koole, Michel, Celen, Sofie, Bormans, Guy, and Van Laere, Koen
- Subjects
CANNABINOIDS ,POSITRON emission tomography ,CANNABINOID receptors ,LABORATORY rats ,EATING disorders ,EPILEPSY - Abstract
Purpose: [F]MK-9470 is an inverse agonist for the type 1 cannabinoid (CB1) receptor allowing its use in PET imaging. We characterized the kinetics of [F]MK-9470 and evaluated its ability to quantify CB1 receptor availability in the rat brain. Methods: Dynamic small-animal PET scans with [F]MK-9470 were performed in Wistar rats on a FOCUS-220 system for up to 10 h. Both plasma and perfused brain homogenates were analysed using HPLC to quantify radiometabolites. Displacement and blocking experiments were done using cold MK-9470 and another inverse agonist, SR141716A. The distribution volume ( V) of [F]MK-9470 was used as a quantitative measure and compared to the use of brain uptake, expressed as SUV, a simplified method of quantification. Results: The percentage of intact [F]MK-9470 in arterial plasma samples was 80 ± 23 % at 10 min, 38 ± 30 % at 40 min and 13 ± 14 % at 210 min. A polar radiometabolite fraction was detected in plasma and brain tissue. The brain radiometabolite concentration was uniform across the whole brain. Displacement and pretreatment studies showed that 56 % of the tracer binding was specific and reversible. V values obtained with a one-tissue compartment model plus constrained radiometabolite input had good identifiability (≤10 %). Ignoring the radiometabolite contribution using a one-tissue compartment model alone, i.e. without constrained radiometabolite input, overestimated the [F]MK-9470 V, but was correlated. A correlation between [F]MK-9470 V and SUV in the brain was also found ( R = 0.26-0.33; p ≤ 0.03). Conclusion: While the presence of a brain-penetrating radiometabolite fraction complicates the quantification of [F]MK-9470 in the rat brain, its tracer kinetics can be modelled using a one-tissue compartment model with and without constrained radiometabolite input. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Characterization of the inflammatory response in a photothrombotic stroke model by MRI: implications for stem cell transplantation.
- Author
-
Vandeputte, Caroline, Thomas, Debby, Dresselaers, Tom, Crabbe, Annelies, Verfaillie, Catherine, Baekelandt, Veerle, Laere, Koen, Himmelreich, Uwe, and Van Laere, Koen
- Subjects
MAGNETIC resonance imaging ,CEREBROVASCULAR disease ,IRON oxides ,IMMUNOHISTOCHEMISTRY ,STEM cell transplantation ,CELL metabolism ,IRON metabolism ,PROTEIN metabolism ,THROMBOSIS complications ,CARDIOVASCULAR disease treatment ,STROKE treatment ,ANIMAL experimentation ,BIOLOGICAL models ,BLOOD vessels ,CELLS ,COMPARATIVE studies ,FLUORESCENT antibody technique ,INFLAMMATION ,MACROPHAGES ,RESEARCH methodology ,MEDICAL cooperation ,RATS ,RESEARCH ,STEM cells ,STROKE ,THROMBOSIS ,EVALUATION research ,DISEASE complications - Abstract
Purpose: The aim of this study was to evaluate the specificity of magnetic resonance imaging (MRI) contrast in a photothrombotic (PT) stroke model with and without engraftment of superparamagnetic iron oxide (SPIO)-labeled stem cells.Procedures: We monitored animals with PT stroke versus animals with PT stroke and stem cell engraftment by T(2)/T(2)*w MRI 4-8 h and 2, 4, 6/7 and 14 days after PT induction. Results were correlated with immunohistochemistry.Results: T(2)*w MRI images showed hypointense contrast due to the accumulation of inflammatory cells and corresponding iron accumulation and glial scar formation in the border zone of the lesion, similar as what was observed for SPIO-labeled cells. Histological analysis was thus indispensable to distinguish between labeled transplanted cells and immune cells.Conclusion: These results raise caution regarding the non-invasive monitoring of SPIO-labeled transplanted stem cells by MRI in models that result in a strong inflammatory response. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.